JCEM:甲状腺功能减退者 左旋甲状腺素在参考范围内使用越高越好?

2018-06-26 吴星 环球医学

2018年5月,发表于《J Clin Endocrinol Metab》上的一项研究,考察了左旋甲状腺素(L-T4)剂量的改变对使用其治疗的患者的生活质量、情绪和认知的影响。

2018年5月,发表于《J Clin Endocrinol Metab》上的一项研究,考察了左旋甲状腺素(L-T4)剂量的改变对使用其治疗的患者的生活质量、情绪和认知的影响。

背景:大脑是甲状腺激素的重要靶器官,但是甲状腺功能的差异在参考范围之内或邻近参考范围是否会影响生活质量、情绪或认知是未知的。

方法:总共138名L-T4治疗的甲状腺功能减退和促甲状腺激素(TSH)水平正常的受试者进行了生活质量测量(36项健康调查简表、甲状腺功能低下依赖的生活质量调查问卷)、情绪测量(心境状态量表、情感不稳定量表)和认知测量(执行功能、记忆)。然后,患者以双盲的形式随机分配到未改变、更高或更低L-T4剂量组,并分别针对3个TSH范围(0.34~2.50、2.51~5.60、5.61~12.0mU/L)。基于TSH水平,每6周调整剂量。基线测量在6个月时再评估一次。

结果:研究结束时,根据意愿治疗分析,3组的平均L-T4剂量分别为1.50±0.07、1.32±0.07和0.78±0.08μg/kg(P<0.001),平均TSH水平分别为1.85±0.25、3.93±0.38和9.49±0.80mU/L(P<0.001)。3组在很少的结局上存在微小差异,校正了多重比较后不再具有显著性。受试者不能确定各自的LT-4剂量是如何调整的(P=0.55),但是倾向于他们接受更高剂量的L-T4(P<0.001)。

结论:甲状腺功能减退者改变L-T4剂量到各种TSH水平处于参考范围内或边缘,不会影响生活质量、情绪或认知。尽管缺乏客观获益,但L-T4治疗者倾向于较高的L-T4剂量。基于这些方面的症状,调整甲状腺功能减退者的L-T4剂量,不会造成显著的临床改善。

原始出处:

Samuels MH, Kolobova I, Niederhausen M, et.al. Effects of Altering Levothyroxine (L-T4) Doses on Quality of Life, Mood, and Cognition in L-T4 Treated Subjects. J Clin Endocrinol Metab. 2018 May 1;103(5):1997-2008. doi: 10.1210/jc.2017-02668.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1777808, encodeId=8cd91e7780813, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Nov 27 20:14:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063190, encodeId=ac552063190f9, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed May 15 23:14:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327588, encodeId=8c1532e5885f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Thu Jun 28 06:40:48 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456952, encodeId=9c89145695252, content=<a href='/topic/show?id=864d48113ea' target=_blank style='color:#2F92EE;'>#左旋甲状腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48113, encryptionId=864d48113ea, topicName=左旋甲状腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24a45820141, createdName=liuhuangbo, createdTime=Thu Jun 28 05:14:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327402, encodeId=a0d732e40257, content=学习了谢谢了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPeNmuNF9ibgMfMOAs7Iic5MpiaU8RLmRH67xCKuk5wzfhb7G4ib7ia6z9lrnsTicj1nAUfEOMecZDtvvu/0, createdBy=d7f91939785, createdName=186****0580(小山羊), createdTime=Wed Jun 27 09:58:04 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327190, encodeId=5b7132e190fb, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jun 26 16:02:16 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2018-11-27 smallant2015
  2. [GetPortalCommentsPageByObjectIdResponse(id=1777808, encodeId=8cd91e7780813, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Nov 27 20:14:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063190, encodeId=ac552063190f9, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed May 15 23:14:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327588, encodeId=8c1532e5885f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Thu Jun 28 06:40:48 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456952, encodeId=9c89145695252, content=<a href='/topic/show?id=864d48113ea' target=_blank style='color:#2F92EE;'>#左旋甲状腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48113, encryptionId=864d48113ea, topicName=左旋甲状腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24a45820141, createdName=liuhuangbo, createdTime=Thu Jun 28 05:14:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327402, encodeId=a0d732e40257, content=学习了谢谢了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPeNmuNF9ibgMfMOAs7Iic5MpiaU8RLmRH67xCKuk5wzfhb7G4ib7ia6z9lrnsTicj1nAUfEOMecZDtvvu/0, createdBy=d7f91939785, createdName=186****0580(小山羊), createdTime=Wed Jun 27 09:58:04 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327190, encodeId=5b7132e190fb, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jun 26 16:02:16 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2019-05-15 achengzhao
  3. [GetPortalCommentsPageByObjectIdResponse(id=1777808, encodeId=8cd91e7780813, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Nov 27 20:14:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063190, encodeId=ac552063190f9, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed May 15 23:14:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327588, encodeId=8c1532e5885f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Thu Jun 28 06:40:48 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456952, encodeId=9c89145695252, content=<a href='/topic/show?id=864d48113ea' target=_blank style='color:#2F92EE;'>#左旋甲状腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48113, encryptionId=864d48113ea, topicName=左旋甲状腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24a45820141, createdName=liuhuangbo, createdTime=Thu Jun 28 05:14:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327402, encodeId=a0d732e40257, content=学习了谢谢了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPeNmuNF9ibgMfMOAs7Iic5MpiaU8RLmRH67xCKuk5wzfhb7G4ib7ia6z9lrnsTicj1nAUfEOMecZDtvvu/0, createdBy=d7f91939785, createdName=186****0580(小山羊), createdTime=Wed Jun 27 09:58:04 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327190, encodeId=5b7132e190fb, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jun 26 16:02:16 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2018-06-28 青山颖钰

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1777808, encodeId=8cd91e7780813, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Nov 27 20:14:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063190, encodeId=ac552063190f9, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed May 15 23:14:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327588, encodeId=8c1532e5885f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Thu Jun 28 06:40:48 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456952, encodeId=9c89145695252, content=<a href='/topic/show?id=864d48113ea' target=_blank style='color:#2F92EE;'>#左旋甲状腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48113, encryptionId=864d48113ea, topicName=左旋甲状腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24a45820141, createdName=liuhuangbo, createdTime=Thu Jun 28 05:14:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327402, encodeId=a0d732e40257, content=学习了谢谢了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPeNmuNF9ibgMfMOAs7Iic5MpiaU8RLmRH67xCKuk5wzfhb7G4ib7ia6z9lrnsTicj1nAUfEOMecZDtvvu/0, createdBy=d7f91939785, createdName=186****0580(小山羊), createdTime=Wed Jun 27 09:58:04 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327190, encodeId=5b7132e190fb, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jun 26 16:02:16 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1777808, encodeId=8cd91e7780813, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Nov 27 20:14:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063190, encodeId=ac552063190f9, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed May 15 23:14:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327588, encodeId=8c1532e5885f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Thu Jun 28 06:40:48 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456952, encodeId=9c89145695252, content=<a href='/topic/show?id=864d48113ea' target=_blank style='color:#2F92EE;'>#左旋甲状腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48113, encryptionId=864d48113ea, topicName=左旋甲状腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24a45820141, createdName=liuhuangbo, createdTime=Thu Jun 28 05:14:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327402, encodeId=a0d732e40257, content=学习了谢谢了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPeNmuNF9ibgMfMOAs7Iic5MpiaU8RLmRH67xCKuk5wzfhb7G4ib7ia6z9lrnsTicj1nAUfEOMecZDtvvu/0, createdBy=d7f91939785, createdName=186****0580(小山羊), createdTime=Wed Jun 27 09:58:04 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327190, encodeId=5b7132e190fb, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jun 26 16:02:16 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2018-06-27 186****0580(小山羊)

    学习了谢谢了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1777808, encodeId=8cd91e7780813, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Nov 27 20:14:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063190, encodeId=ac552063190f9, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed May 15 23:14:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327588, encodeId=8c1532e5885f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Thu Jun 28 06:40:48 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456952, encodeId=9c89145695252, content=<a href='/topic/show?id=864d48113ea' target=_blank style='color:#2F92EE;'>#左旋甲状腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48113, encryptionId=864d48113ea, topicName=左旋甲状腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24a45820141, createdName=liuhuangbo, createdTime=Thu Jun 28 05:14:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327402, encodeId=a0d732e40257, content=学习了谢谢了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPeNmuNF9ibgMfMOAs7Iic5MpiaU8RLmRH67xCKuk5wzfhb7G4ib7ia6z9lrnsTicj1nAUfEOMecZDtvvu/0, createdBy=d7f91939785, createdName=186****0580(小山羊), createdTime=Wed Jun 27 09:58:04 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327190, encodeId=5b7132e190fb, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jun 26 16:02:16 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2018-06-26 1ddf0692m34(暂无匿称)

    学习了.长知识

    0

相关资讯

LANCET:快速了解甲状腺功能减退!

甲状腺功能减退是甲状腺激素缺乏症的常见病症,其容易诊断和治疗;但如果未经治疗,在严重的情况下可以致命。甲状腺功能减退的定义是基于相关生化参数的统计参考范围,但是这一方式成为一个争论的问题。甲状腺功能减退症的临床表现从有生命危险到无体征或症状。成人最常见的症状是疲劳、嗜睡、不耐受冷、体重增加、便秘、声音变化和皮肤干燥,但这些临床表现可能因年龄和性别而异。目前的标准治疗是使用左甲状腺素进行甲状腺激素替

Blood:甲状腺激素通过TR-KLF9轴调节造血功能。

先天性甲状腺功能减退(CH)是一种最常发生的内分泌疾病,常伴有贫血和免疫缺陷,而其机制尚未完全清楚。

注意!牛奶或可影响左旋甲状腺素吸收

甲状腺功能减退症是最常见的甲状腺疾病之一,由于缺碘、自身免疫变化、辐射损伤等因素引起的甲状腺本身合成和分泌甲状腺激素减少引起的甲减,称为原发性甲减。占全部(原发性和继发性)甲减的99%以上。需要长期服用左甲状腺素钠(L-T4)治疗,甚至需要终生服药。

2017 专家共识报告:难治性甲状腺功能减退的诊断和治疗

经常有甲状腺功能减退的患者对标准激素替代治疗不敏感而额外需要大剂量左旋甲状腺素,本文主要针对难治性甲状腺功能减退的诊断和治疗等内容提出基本管理原则和策略。

看看国际上是如何处理妊娠期甲减的!

女性,28岁,早孕,但由于呕吐频繁,恶心症状严重,前来就诊,后被诊断出妊娠期甲状腺功能减退症。通过学习此病例,我们一起来了解一下国际上对于妊娠合并甲状腺功能减退症的治疗原则,并掌握甲状腺激素替代治疗的适应证等问题。

盘点:甲状腺功能减退近期重要研究进展

甲减,是指由于甲状腺激素合成和分泌减少、或组织利用不足导致的全身代谢减低综合征。病因主要为自身免疫性损伤、甲状腺破坏、甲状腺激素合成障碍、缺碘或服药某些药物等。临床上按照甲状腺功能减低的程度分为临床甲减和亚临床甲减。主要表现为畏寒、嗜睡、体重增加、便秘、记忆力减退等,严重者可出现黏液性水肿昏迷等危险情况。这里梅斯小编整理了近期关于甲减的重要研究进展与大家分享。【1】妊娠期亚临床甲减与早产相关?